DxPG80 does only one thing:
detect and measure hPG80
in human plasma
But it is the only test that provides physicians with new, highly accurate, reliable, reproducible and cost-effective information on the presence of hPG80 in their patients' blood.
DxPG80 IVD test is CE marqued under the project name cancerREAD. Regulatory revisions are ongoing.
One tool: two applications
1. > Help Cancer Susceptibility detection
DxPG80.smart is a new tool to help detect various types of cancer at an early stage. Confirm diagnostic and screening tests.
Aid to confirm current tests and for early cancer screening
An aid to detect cancer progression or relapse
DxPG80.smart is also a confirmatory tool for physicians clinical decision in case the other diagnostic tests give results at the limit of the interpretation.
DxPG80.smart should be considered as a clinical decision aid.
2. > Help Follow-up
An aid to detect cancer progression or relapse. DxPG80.lab is a new tool for patient follow-up. Its goal is to help evaluate a given therapeutic strategy objectively.
of cancer patients
Providing a new tool to help follow up on patients
DxPG80.lab is an efficient and inexpensive new tool to help you to monitor treatment efficiency during and after therapy. Simple, reliable, and reproducible,
DxPG80.lab detects progastrin in a cancer patient’s blood.
A new tool to help physicians to detect multiple cancers susceptibility at early stages
ECS-progastrin has developed the first true test for helping early cancer screening working for multiple cancers and meeting all these criteria. Called DxPG80, this IVD test is able to detect a specific biomarker in the blood: hPG80 (Progastrin).
In almost all types of cancers, at the earliest stages of development, there is an uncontrolled activation of the Wnt oncogenic pathway. This uncontrolled activation of the Wnt oncogenic pathway is vital for the cancer cells to grow and survive. It induces the expression of multiple genes required for the cancer cells to grow and survive. Among these multiple genes, there is the gene coding for our target: Progastrin.